Galderma could still raise guidance and beat expectations when it reports first-half results despite the U.S. Food and Drug Administration's decision not to approve its Relfydess injection, Jefferies analysts say in a research note. The decision has a minor effect on the Swiss skincare specialist's prospects, even if it drives near-term stock weakness, the analysts say. This poses no risk to the company's full-year guidance, and continuing strength in its dermatological skincare business means there is still room for an upgrade to top-line expectations, the analysts add. Shares in Galderma fall 5.6%. (adria.calatayud@wsj.com)
Dow Jones Newswires
Galderma Could Still Raise Guidance Despite Relfydess Setback — Market Talk
Galderma could still raise guidance and beat expectations when it reports first-half results despite the U.S. Food and Drug Administration's decision not to approve its Relfydess injection, Jefferies analysts say in a research note. The decision has a minor effect on the Swiss skincare specialist's…